GliflOzin in eLderly Diabetic patiENts: A praGmatic Intraclass Evaluation Trial
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 1167 participants.
Also called NCT04796428
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 1,167 participants
- Sponsor
- Center for Outcomes Research and Clinical Epidemiology, Italy
- Registry
-
NCT04796428
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Unknown status
Technical summary
Registry record NCT04796428. Randomized; single masking; primary purpose treatment. Start 2021-06-30 (anticipated); primary completion 2023-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- GliflOzin in eLderly Diabetic patiENts: A praGmatic Intraclass Evaluation Trial
- Acronym
- GOLDEN-AGE
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Canagliflozin
- Intervention (Drug)
- Dapagliflozin
- Intervention (Drug)
- Empagliflozin
- Lead sponsor
- Center for Outcomes Research and Clinical Epidemiology, Italy
- Collaborator
- Italian Society of Diabetology
Record details
- Record id
cardio:ct-nct04796428- Content hash
fcb794a5474d3b63e47f64f1a0236a0c8d18a530ea53a1330b2b6b0a81f7bbc2